BioSpace News Archive

CTI BioPharma Corp. (Nasdaq: CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020 in CTI BioPharma’s common stock and preferred stock will receive a subscription right entitling them to purchase their pro rata share of the $60 million offering amount.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the upcoming presentation of EEG data from its Phase 2 study at the American Clinical Neurophysiology Society (ACNS) 2020 Annual Meeting in New Orleans, Louisiana on February 7, 2020.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today confirms that the Company fell below the Nasdaq’s minimum market value of listed securities (“MVLS”) threshold of $35 million on January 31, 2020.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has completed enrollment of approximately 50% of the 525 patients planned for its Phase III ACRobat™ trial to evaluate its drug candidate Piclidenoson as a first-line treatment for rheumatoid arthritis (RA).

CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the appointment of Alison L. Hannah, M.D., as senior vice president and chief medical officer.

As Eisai Inc. continues to bring innovative medicines and dynamic solutions to the marketplace, the company announces today the expansion of its leadership team to include two key appointments in the areas of Corporate Affairs and Market Access.

Patients from 30 Countries / Territories and 47 States Traveled to CIGC for Groundbreaking Minimally Invasive Surgical Techniques

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis (RRP), a rare and orphan disease, in the open access scientific journal Vaccines (MDPI)

$250,000 in Vilcek Foundation Prizes awarded to Xiaowei Zhuang, Kivanç Birsoy, Viviana Gradinaru, and Martin Jonikas.